CION Ameerpet
A pathology report is written for clinicians, and it is the most consequential document in your care. Almost every line has a plain-English meaning — and knowing what each one is telling you makes the treatment conversation an entirely different experience.
A pathology report can run to several pages of dense technical description, and it is genuinely intimidating. But the treatment conversation turns largely on three things: the subtype, the grade, and the stage. If you locate only those three, you will understand most of what is being decided.
Subtype is what kind of ovarian cancer it is. This matters more than people expect — ovarian cancer is not one disease but several, and the subtypes behave differently, respond differently to chemotherapy and carry different outlooks. High-grade serous is by far the commonest; clear-cell, endometrioid, mucinous and others behave quite differently.
Grade describes how abnormal the cells look under the microscope and how fast they are dividing — low-grade tumours grow slowly, high-grade ones aggressively. Stage describes how far disease has spread, and in ovarian cancer it is determined surgically rather than on a scan, from the systematic samples taken during the operation. Everything else in the report supports these three.
Ovarian cancer is several diseases. High-grade serous is commonest; the others behave and respond differently.
How abnormal the cells look and how fast they divide. Low-grade grows slowly; high-grade does not.
Determined surgically from systematic samples, not from a scan. It drives most of the treatment decision.
Ovarian cancer is not one disease. The subtypes differ so fundamentally — in the cells they arise from, the mutations they carry, how they behave and how they respond to treatment — that researchers increasingly regard them as separate diseases that happen to share an anatomical location. High-grade serous carcinoma is the commonest and is typically chemo-sensitive but presents late. Clear-cell and mucinous carcinomas are less common, are often found earlier, and are typically less responsive to standard platinum chemotherapy. This is why the subtype line on your report shapes the treatment discussion as much as the stage does. Source: WHO classification of ovarian tumours; NCCN Ovarian Cancer guidelines.
Find the wording yours uses. The report may not contain all of these, depending on what was sampled.
| The report says | Plain English | Why it matters |
|---|---|---|
| High-grade serous carcinoma | The commonest ovarian cancer subtype. | Typically chemo-sensitive; often presents at advanced stage. Strongly linked to BRCA. |
| Low-grade serous carcinoma | A distinct, slower-growing serous tumour. | Behaves quite differently from high-grade; less chemo-sensitive, often hormone-responsive. |
| Clear-cell carcinoma | A subtype often arising in endometriosis. | Frequently found at earlier stage; typically less responsive to standard chemotherapy. |
| Endometrioid carcinoma | Resembles the lining of the womb; also linked to endometriosis. | Often earlier stage and lower grade. Sometimes coexists with womb cancer. |
| Mucinous carcinoma | Contains mucin-producing cells. | Uncommon. Often normal CA-125. A bowel primary must be excluded. |
| Borderline tumour / low malignant potential | Abnormal cells that do not invade surrounding tissue. | Substantially better outlook than carcinoma. Often fertility-sparing surgery is possible. |
| Grade 1 / low grade | Cells still resemble normal tissue; slow-growing. | Generally a more favourable outlook. |
| Grade 3 / high grade | Cells markedly abnormal; dividing rapidly. | More aggressive, but frequently more chemo-sensitive. |
| Capsule intact / not breached | The tumour was contained and not ruptured. | Keeps the stage lower. This is why masses are removed intact. |
| Peritoneal washings positive | Malignant cells found in fluid washed from the abdomen. | Raises the stage even where nothing was visible to the eye. |
| Omental deposits | Tumour found in the fatty apron over the bowel. | A common site of spread; indicates more advanced stage. |
| Lymph nodes: 0/12 positive | None of the twelve nodes examined contained tumour. | Node-negative disease. The denominator shows how thoroughly it was sampled. |
| Lymphovascular invasion | Tumour cells seen inside small blood or lymph vessels. | Indicates a route by which disease can spread. |
| Immunohistochemistry: PAX8, WT1, p53 | Protein stains used to confirm the tissue of origin. | Confirms the tumour is ovarian rather than spread from elsewhere. |
| Ki-67 index | The proportion of cells actively dividing. | A measure of how fast the tumour is growing. |
*A single alarming-sounding phrase rarely decides anything on its own. Pathologists and oncologists read the whole report together with the imaging and the operative findings.
Each element feeds into a specific decision. This is roughly how the conversation is built.
Stage is determined surgically in ovarian cancer, from systematic samples taken during the operation — washings, peritoneal biopsies, omentum and lymph nodes, taken even where everything looked normal. Microscopic disease in those samples changes the stage and therefore the treatment.
Very early, low-grade, completely removed disease may need no chemotherapy at all. More advanced disease is treated with platinum-based chemotherapy after surgery, or before it where complete removal was not initially achievable. This is why incomplete staging matters so much — an operation that did not sample properly leaves the decision on uncertain ground.
High-grade serous carcinoma is typically chemo-sensitive, which is genuinely important — it often responds well to platinum-based treatment even at advanced stage. Clear-cell and mucinous carcinomas are typically less responsive to the same regimens, which changes both expectations and sometimes the regimen itself.
Low-grade serous carcinoma behaves differently again — slower growing, less chemo-sensitive, and often hormone-receptor-positive, which opens hormonal treatment options that would not apply to a high-grade tumour.
If the tumour was removed whole with its capsule unbreached, and washings were negative, disease was genuinely contained — which keeps the stage lower and may mean less treatment is needed.
If the capsule ruptured, whether before or during surgery, that is documented because it affects the stage. This is precisely why surgeons take such care to remove ovarian masses intact, and why percutaneous biopsy is generally avoided. See why biopsy is avoided.
This appears in the operation note more than the pathology report, but it belongs in the same conversation. Whether all visible disease was removed — complete cytoreduction — is one of the strongest influences on outcome in advanced ovarian cancer.
It is worth asking directly whether any visible disease remained and, if so, roughly how much. It is a specific question with a specific answer, and it shapes what the treatment is trying to achieve. See debulking surgery.
Beyond the microscope, tumour tissue is tested for homologous recombination deficiency, and germline testing is offered for BRCA1 and BRCA2. These results guide maintenance therapy after chemotherapy — a PARP-inhibitor-class drug is most effective where the repair pathway is broken.
If your report predates this testing or does not mention it, ask. Both are now standard for epithelial ovarian cancer and both are delivered in-house at CION. See HRD testing.
Occasionally the final report differs from what the frozen section suggested during surgery, or identifies a tumour that is not ovarian in origin at all — a mucinous carcinoma spreading from the bowel, for instance, or a lymphoma.
Where that happens the case returns to a tumour board and the treatment plan changes accordingly. It is unsettling but it is the system working: the definitive answer is the full histopathology, and acting on it correctly is more important than acting on the preliminary one quickly.
All reasonable, and asking them tends to produce a considerably more useful conversation.
These shape what treatment is likely to achieve as much as the stage does. Ask for both explicitly.
Ask which sites were sampled — washings, omentum, peritoneum, nodes. Complete staging matters.
Complete cytoreduction strongly influences outcome. It is a specific question with a specific answer.
Both are standard for epithelial ovarian cancer and both guide maintenance therapy.
Multidisciplinary review before a treatment plan is set is standard, not an optional extra.
You are entitled to it, you will need it at every future appointment, and any second opinion starts with reading it.
Keep the full report rather than a summary letter. It is the single most important document in your care and you will be asked for it repeatedly.
Not a summary letter. You are entitled to it, you will need it at every future appointment, and any second opinion begins with reading it.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring the report — it is the document that determines everything that follows.
Pathology reports are frequently handed over in an appointment where a great deal else is being said, at a moment when very little is being absorbed. Women commonly leave knowing the word cancer was used and almost nothing else — then read the document alone that evening and search each term individually.
Your first consultation at CION is free and runs to about 45 minutes, which is long enough to go through the report properly rather than summarise it in a sentence. Bring the full document. If you are seeking a second opinion, this is exactly the right thing to bring — a second opinion on ovarian cancer begins with reading the pathology, not with repeating the tests.
Where treatment follows, chemotherapy and maintenance therapy including PARP-inhibitor-class treatment are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, as are genetic counselling and BRCA and HRD testing. Debulking and staging surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Every case that raises a question is reviewed at a tumour board rather than decided by one clinician.
Free and unhurried. Long enough to go through the report line by line rather than summarise it.
Not a summary letter. A second opinion on ovarian cancer begins with reading the pathology.
Multidisciplinary review — medical oncology, imaging and pathology — before a plan is set.
BRCA and HRD testing, chemotherapy and maintenance therapy across 35+ centres.
This is a word worth looking for specifically, because it changes the picture substantially and is easily missed among the technical language. A borderline tumour — also written as tumour of low malignant potential — has abnormal cells that do not invade the surrounding tissue in the way a carcinoma does.
It sits genuinely between benign and malignant. Borderline tumours occur more often in younger women, are usually confined to the ovary when found, and carry a substantially better outlook than ovarian carcinoma. They are treated primarily with surgery, and chemotherapy is frequently not needed at all.
For a younger woman there is a further point that matters enormously: because these tumours are often confined to one ovary, fertility-sparing surgery is frequently possible — removing the affected ovary while preserving the other and the uterus. If your report contains this word and nobody has discussed fertility with you, raise it. See fertility and ovarian cancer.
Abnormal cells that do not invade surrounding tissue the way a carcinoma does.
Usually confined to the ovary when found, and more common in younger women.
Chemotherapy is frequently not needed. Treatment is primarily surgical.
Removing the affected ovary while preserving the other and the uterus. Raise it if nobody has.
Three lines carry most of the weight: the subtype, the grade and the stage. Subtype is what kind of ovarian cancer it is — high-grade serous is by far the commonest, and clear-cell, endometrioid, mucinous and low-grade serous all behave differently and respond differently to treatment. Grade describes how abnormal the cells look and how fast they are dividing. Stage describes how far disease has spread and, in ovarian cancer, is determined surgically from systematic samples rather than from a scan. If you locate only those three, you will understand most of what is being decided.
Because ovarian cancer is not one disease. The subtypes differ so fundamentally — in the cells they arise from, the mutations they carry, how they behave and how they respond to chemotherapy — that they are increasingly regarded as separate diseases sharing an anatomical location. High-grade serous carcinoma is typically chemo-sensitive but often presents at advanced stage. Clear-cell and mucinous carcinomas are frequently found earlier but are typically less responsive to standard platinum chemotherapy. Low-grade serous grows more slowly and is often hormone-responsive, opening treatment options that would not apply otherwise.
During surgery, fluid is washed around the abdominal cavity and then collected and examined for cancer cells. A positive result means malignant cells were found floating in that fluid, even if no tumour deposits were visible to the surgeon's eye. It raises the stage, because it indicates disease has escaped the ovary into the abdominal cavity. This is exactly why staging in ovarian cancer requires systematic sampling during the operation rather than relying on a scan — microscopic disease that no imaging could detect still changes the stage and therefore the treatment.
It sits genuinely between benign and malignant, and it is considerably better news than a carcinoma. A borderline tumour, also called a tumour of low malignant potential, has abnormal cells that do not invade the surrounding tissue in the way a cancer does. These tumours occur more often in younger women, are usually confined to the ovary when found, and carry a substantially better outlook. They are treated primarily with surgery and chemotherapy is frequently not needed. For younger women, fertility-sparing surgery is often possible — if nobody has discussed that with you, raise it.
A result written as something like 0 out of 12 means twelve lymph nodes were removed and examined, and none contained tumour — node-negative disease. The denominator matters as well as the numerator: it shows how thoroughly the nodes were sampled, and a larger number examined gives more confidence in a negative result. If nodes are positive, the number involved and their location feed into the stage. Node sampling is part of systematic surgical staging, done even where nodes appeared normal to the eye, because microscopic involvement changes the stage.
These are immunohistochemical stains — tests that detect specific proteins in the tumour cells, used to confirm what kind of tumour it is and where it originated. They matter most for confirming that a cancer is genuinely ovarian rather than having spread from somewhere else, which changes treatment entirely. This is particularly important for mucinous tumours, where a bowel primary must be excluded. Certain patterns also support specific subtype diagnoses. They are a normal part of a thorough report rather than a sign of any complication.
The first consultation is free and runs to about 45 minutes, which is long enough to go through your report line by line rather than summarise it. Bring the full document rather than a summary letter — if you are seeking a second opinion, this is exactly the right thing to bring, since a second opinion on ovarian cancer begins with reading the pathology. Chemotherapy and maintenance therapy, genetic counselling and BRCA and HRD testing are all delivered in-house at CION across more than 35 centres. Debulking and staging surgery is coordinated with specialist partner centres and may be billed there.